L-N^τ-methylhistidine methyl ester dihydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-N^τ-methylhistidine methyl ester dihydrochloride
• 英文别名: H-His(τ-Me)-OMe dihydrochloride；N(π)-methyl-1-histidine methyl ester dihydrochlorid；1-methylhistidine methyl ester dihydrochloride；1-methyl-(S)-histidine methyl ester dihydrochloride；methyl (2S)-2-amino-3-(1-methyl-1H-imidazol-4-yl)propanoate dihydrochloride；Nϖ-methyl-L-histidine methyl ester dihydrochloride；H-His(1-Me)-OMe HCl；methyl (2S)-2-amino-3-(1-methylimidazol-4-yl)propanoate;hydrochloride
• 化学式: C₈H₁₃N₃O₂*2ClH
• 分子量: 256.132
• InChiKey: QLLXZYBGSICACM-FJXQXJEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.12
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  L-N^τ-methylhistidine methyl ester dihydrochloride 在 水 、 氯甲酸异丙酯 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 26.0h， 生成 L-鲸肌肽
  参考文献：
  名称：

  一种N(π)-甲基-L-组氨酸衍生物的制备方法及其在合成鲸肌肽中的应用

  摘要：

  本发明涉及一种N(π)‑甲基‑L‑组氨酸衍生物的制备方法，以及由合成的N(π)‑甲基‑L‑组氨酸衍生物制备鹅肌肽的方法，本发明所述方法原辅料廉价易得，选择性好，收率高；操作简单易行、工艺稳定、易于控制、反应后处理方便、产物收率好，纯度高，可以经济方便地用于工业化生产。

  公开号：

  CN108997187A
• 作为产物：
  描述：

  S-(+)-7-Methoxycarbonyl-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidin-5-on 在 盐酸 作用下， 以 水 、 乙腈 为溶剂， 反应 70.0h， 生成 L-N^τ-methylhistidine methyl ester dihydrochloride
  参考文献：
  名称：

  Carnosine protects cardiac myocytes against lipid peroxidation products

  摘要：

  Endogenous histidyl dipeptides such as carnosine (-alanine-l-histidine) form conjugates with lipid peroxidation products such as 4-hydroxy-trans-2-nonenal (HNE and acrolein), chelate metals, and protect against myocardial ischemic injury. Nevertheless, it is unclear whether these peptides protect against cardiac injury by directly reacting with lipid peroxidation products. Hence, to examine whether changes in the structure of carnosine could affect its aldehyde reactivity and metal chelating ability, we synthesized methylated analogs of carnosine, balenine (-alanine-N-methylhistidine) and dimethyl balenine (DMB), and measured their aldehyde reactivity and metal chelating properties. We found that methylation of N residue of imidazole ring (balenine) or trimethylation of carnosine backbone at N residue of imidazole ring and terminal amine group dimethyl balenine (DMB) abolishes the ability of these peptides to react with HNE. Incubation of balenine with acrolein resulted in the formation of single product (m/z 297), whereas DMB did not react with acrolein. In comparison with carnosine, balenine exhibited moderate acrolein quenching capacity. The Fe2+ chelating ability of balenine was higher than that of carnosine, whereas DMB lacked chelating capacity. Pretreatment of cardiac myocytes with carnosine increased the mean lifetime of myocytes superfused with HNE or acrolein compared with balenine or DMB. Collectively, these results suggest that carnosine protects cardiac myocytes against HNE and acrolein toxicity by directly reacting with these aldehydes. This reaction involves both the amino group of -alanyl residue and the imidazole residue of l-histidine. Methylation of these sites prevents or abolishes the aldehyde reactivity of carnosine, alters its metal-chelating property, and diminishes its ability to prevent electrophilic injury.

  DOI：

  10.1007/s00726-018-2676-6

文献信息

• Peptide-tethered monodentate and chelating histidylidene metal complexes: synthesis and application in catalytic hydrosilylation
  作者：Angèle Monney、Flavia Nastri、Martin Albrecht

  DOI：10.1039/c3dt50424g

  日期：——

  abstraction from the rhodium centre, while tyrosine remained non-coordinating under identical conditions. High catalytic activities in hydrosilylation were achieved with all peptide-based rhodium complexes. The cationic SMet,CHis*-bidentate peptide rhodium catalyst outperformed the monodentate neutral peptide complexes and constitutes one of the most efficient rhodium carbene catalysts for hydrosilylation

  的Ñ δ，Ñ ε -dimethylated histidinium盐（他*）被拴在寡肽和金属化，以形成的Ir（III）和Rh（我）NHC络合物。基于肽的组氨酸二亚胺配合物仅含有丙氨酸，合成了Ala–Ala–His * – [M]和Ala–Ala–Ala–His * – [M]（[M] = 铑（鳕鱼）Cl，Ir（Cp *）Cl 2）以及具有潜在螯合作用的寡肽复合物蛋氨酸 和酪氨酸残基，Met–Ala–Ala–His * –铑（鳕鱼）Cl 和 提尔–Ala–Ala–His * –铑（鳕鱼）Cl。从铑中心提取卤化物诱导了含有蛋氨酸的组氨酸亚基配体的螯合，而酪氨酸在相同条件下仍然不协调。所有基于肽的铑配合物均能实现氢化硅烷化中的高催化活性。阳离子S Met，C His *-双齿肽铑催化剂的性能优于单齿中性肽络合物，构成了氢化硅烷化最有效的铑卡宾催化剂之一，为肽在催化中用作N-杂环卡宾配体提供了新的机会。
• Inhibitors of cysteine proteases and methods of use thereof
  申请人：Pardes Biosciences, Inc.

  公开号：US11124497B1

  公开（公告）日：2021-09-21

  The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease. Exemplary compounds provided include Formula II-I, where R3, RB are provided herein:

  该披露提供了具有战斗头的化合物及其在治疗医学疾病或紊乱，如病毒感染方面的用途。提供了制药组合物和制备各种带有战斗头的化合物的方法。这些化合物被认为能够抑制蛋白酶，如3C、CL-或3CL样蛋白酶。提供的示例化合物包括Formula II-I，其中R3、RB如下所示：
• Pharmaceuticals
  申请人：——

  公开号：US20020147229A1

  公开（公告）日：2002-10-10

  The present invention provides compounds of formula (I) 1 as well as the use of such compounds in pharmaceutical compositions and methods of treatment. The compounds described herein represent a class of TAFIla inhibitors suitable for use in treating conditions such as thrombosis, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

  本发明提供了式(I)1的化合物，以及这些化合物在制药组合物和治疗方法中的应用。本文描述的化合物代表了一类适用于治疗血栓形成、动脉粥样硬化、粘连、皮肤瘢痕、癌症、纤维化疾病、炎症性疾病以及那些受益于维持或增强体内激肽酶激活因子Ⅰ（TAFIla）抑制剂的疾病的化合物。
• NOVEL HISTIDINE DERIVATIVES
  申请人：Nakazawa Yoshitaka

  公开号：US20100152459A1

  公开（公告）日：2010-06-17

  The present invention is to provide a novel compound which is useful as a pharmaceutical agent such as an analgesic. The present invention is to provide the novel histidine derivative having an excellent analgesic action and the like. The compound of the present invention has a very high intermigration into the blood upon oral administration and is very useful as a pharmaceutical agent, especially an analgesic for the treatment of acute or chronic pain diseases and of neuropathic pain diseases.

  本发明提供了一种新型化合物，可用作药物剂，如镇痛剂。本发明提供了具有出色镇痛作用的新型组氨酸衍生物等。本发明的化合物在口服后能够迅速进入血液循环，并且非常适用作为药物剂，特别是用于治疗急性或慢性疼痛疾病和神经病理性疼痛疾病的镇痛剂。
• 一种鹅肌肽及其中间体的制备方法
  申请人：南京纽邦生物科技有限公司

  公开号：CN109748874A

  公开（公告）日：2019-05-14

  本发明提供了两种鹅肌肽的制备方法，以及一种合成鹅肌肽中间体的制备方法，操作简单易行、工艺稳定、易于控制、反应后处理方便、产物收率好，纯度高，可以经济方便地用于工业化生产。